Latest news articles

Added 2 months ago Drug news

Recordati to market Cystagon in Europe for nephropathic cystinosis.- Mylan

Recordati announces the completion of an agreement with Mylan for the acquisition of the rights to Cystagon (cysteamine bitartrate), indicated...

Added 1 year ago Congress news

Late Breaking Clinical Trials from ERA-EDTA

Latest breaking clinical trial information from the 54th European Renal Association & European Dialysis and Transplant Association (ERA-EDTA) Congress, Madrid, 3-6 June, 2017

Added 1 year ago Drug news

The European Union Commission grants marketing authorization for Cystadrops 3.8mg/mL. for treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis.- Recordati

Recordati announces that the European Union Commission has granted the European marketing authorization for its orphan medicinal product Cystadrops 3.8mg/mL....

Search all news articles for Nephritis, nephrosis, renal sclerosis

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.



See information on best practice in solid organ transplantation, and expert discussions on related hot topics.

Fabry Disease

Fabry Disease

Explore the pathophysiology and treatment options for Fabry disease, a deficiency of the lysosomal enzyme alpha-galactosidase A

Load more


KDIGO Clinical Practice Guideline for Glomerulonephritis

The 2011 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Glomerulonephritis (GN) aims to assist practitioners caring for adults and children with GN.

Added 6 years ago

Search all guidelines for Nephritis, nephrosis, renal sclerosis

Journal articles

Fcγ Receptor IIIa Single–Nucleotide Polymorphisms and Haplotypes Affect Human IgG Binding and Are Associated With Lupus Nephritis in African Americans

Objective:To investigate whether the Fcγ receptor IIIa–66L/R/H (FcγRIIIa–66L/R/H) polymorphism influences net effective receptor function and to assess if the FCGR3A...

Added 4 years ago

Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study

Objective:To investigate the efficacy and safety of ocrelizumab in patients with class III/IV lupus nephritis (LN).Methods:Patients were randomized 1:1:1 to...

Added 4 years ago

Permeability factors in nephrotic syndrome and focal segmental glomerulosclerosis

Circulating permeability factors have been identified in the plasma of patients with focal segmental glomerulosclerosis (FSGS). Post-transplant recurrence of proteinuria,...

Added 5 years ago

Search all journal articles for Nephritis, nephrosis, renal sclerosis